MedTrace Logo

Sentinel Node Biopsy in Breast Cancer Patients

NCT01351974 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3369

Last updated 2011-05-30

No results posted yet for this study

Summary

Axillary lymph node dissection (ALND) was previously the standard axillary staging procedure in breast cancer patients. However, ALND is accompanied by a considerable morbidity, and sentinel lymph node biopsy (SLNB) evolved as a mean to decrease this morbidity. Between September 2000 and January 2004 breast cancer patients were included in the Swedish Sentinel Node Multicenter Cohort Study with the intent of studying axillary recurrence after negative SLNB for patients in which completion ALND were omitted. The patients were followed prospectively and events (local, regional and distant recurrences and deaths) were registered. The primary endpoint was axillary recurrence and secondary endpoints were disease-free, cancer-specific and overall survival.

Conditions

Sponsors & Collaborators

  • Swedish Cancer Society

    collaborator OTHER

  • Uppsala University

    lead OTHER

Principal Investigators

  • Leif Bergkvist, M.D. Ph.D. · Centre for Clinical Research, Uppsala University

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-09-30
Primary Completion
2004-01-31
Completion
2004-01-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01351974 on ClinicalTrials.gov